Showing 7111-7120 of 9550 results for "".
- FDA Adds Third Approved Indication for Botox Cosmetic: Forehead Lineshttps://practicaldermatology.com/news/fda-adds-third-approved-indication-for-botox-cosmetic-forehead-lines/2458032/Allergan plc's Botox Cosmetic received ts third FDA indication—the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults. This approval makes the brand the first and only neurotoxin indicated for three facial tre
- Sciton and the Young Survival Coalition Partner for Breast Cancer Awarenesshttps://practicaldermatology.com/news/sciton-and-the-young-survival-coalition-partner-for-breast-cancer-awareness/2458041/Sciton, Inc.’s Women's Health Group division and the Young Survival Coalition (YSC) are partnering to raise awareness about women's vaginal health, in particular, those who are recovering from breast can
- Dr. Michael H. Gold Joins AIVITA Scientific Advisory Boardhttps://practicaldermatology.com/news/dr-michael-h-gold-joins-aivita-scientific-advisory-board/2458042/Nashville dermatologist Michael H. Gold, MD, has joined AIVITA Biomedical’s Scientific Advisory Board. His addition comes as AIVITA prepares to launch its upcoming ROOT OF SKINTM line of rejuvenating skincare products. Dr. Gold,
- New Data: Aclaris' A-101 40% Safely Banishes Facial SK Lesionshttps://practicaldermatology.com/news/new-data-aclaris-a-101-40-safely-banishes-facial-sk-lesions/2458044/Good news for Aclaris. New data suggest that their drug candidate A-101 40 percent may be an appealing option to remove seborrheic keratosis (SK) lesions in highly visible areas, such as the face, with minimal risk of s
- Five-Year Data Show Sustained Efficacy, Safety for Cosentyxhttps://practicaldermatology.com/news/five-year-data-show-sustained-efficacy-safety-for-cosentyx/2458054/Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase III data. These data were presented for
- FDA Approves T.R.U.E. Test Ready-To-Use Patch Test for Pediatric Usehttps://practicaldermatology.com/news/fda-approves-true-test-ready-to-use-patch-test-for-pediatric-use/2458057/The FDA has approved SmartPractice's T.R.U.E. TEST (truetest.com) ready-to-use patch test panels for pediatric patients as young as 6 years of age. T.R.U.E. TEST is the only FDA-approved product for diagnosing allergic contact derm
- Deion Sanders Named Brand Ambassador for Botox Cosmetichttps://practicaldermatology.com/news/deion-sanders-named-brand-ambassador-for-botox-cosmetic/2458062/NFL analyst and philanthropist Deion Sanders, the only athlete to play in both the Super Bowl™ and World Series™, is the new brand ambassador for BOTOX® Cosmetic. Allergan also released two vide
- Cemiplimab Receives FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinomahttps://practicaldermatology.com/news/cemiplimab-receives-fda-breakthrough-therapy-designation-for-advanced-cutaneous-squamous-cell-carcinoma/2458063/The FDA has granted Breakthrough Therapy designation status to Regeneron Pharmaceuticals, Inc. and Sanofi's cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC. Cemiplimab is an
- Galderma Names New Managers of Prescription Business and Aesthetic & Corrective Business Units; Dr. Kelly Huang to Obalonhttps://practicaldermatology.com/news/alisa-lask-to-oversee-galdermas-aesthetic-corrective-business-unit-dr-kelly-huang-to-obalon/2458064/Galdmera has named new managers of its Prescription Business and Aesthetic & Corrective Business units in the United States. Chris Chapman is Galderma’s new Vice President and General Manager of Prescription Business and Alisa Lask <
- RXI Completes Enrollment of Phase 2 Study of Samcyprone for Cutaneous Wartshttps://practicaldermatology.com/news/rxi-completes-enrollment-of-phase-2-study-of-samcyprone-for-cutaneous-warts/2458067/RXi Pharmaceuticals Corporation completed enrollment in its Phase 2 clinical trial, RXI-SCP-1502, with Samcyprone™for the clearance of cutaneous warts. Samcyprone™ is a proprietary topical formulation of the small molecule diphenylcyclopr